Suboxone is not approved for pain management. The FDA approved it specifically for treating opioid dependence, and its prescribing label explicitly states that it “is not appropriate as an analgesic.” However, the active ingredient in Suboxone, buprenorphine, is a potent pain reliever, and some providers do prescribe Suboxone off-label for chronic pain, particularly in patients who also have opioid use disorder.
Why Suboxone Contains a Pain Reliever but Isn’t a Pain Drug
Suboxone combines two ingredients: buprenorphine and naloxone. Buprenorphine is an opioid that binds tightly to the same receptors as morphine and oxycodone, but it activates them only partially. This partial activation is enough to reduce cravings and withdrawal symptoms in people with opioid dependence, which is why the drug was approved for that purpose. It also happens to provide strong pain relief, but Suboxone was never studied or marketed as a painkiller.
Other formulations of buprenorphine are FDA-approved specifically for pain. A low-dose skin patch delivers buprenorphine continuously for chronic pain, and a buccal film (placed against the cheek) is approved for pain severe enough to require around-the-clock opioid treatment. These products contain buprenorphine alone, at doses calibrated for pain management rather than addiction treatment.
The naloxone in Suboxone exists as a misuse deterrent. It blocks opioid receptors if the drug is injected, which would trigger withdrawal. When Suboxone is taken as directed, dissolved under the tongue, very little naloxone actually reaches the bloodstream. FDA pharmacokinetic reviews confirmed that naloxone does not meaningfully affect how buprenorphine works when the drug is taken sublingually, so it doesn’t cancel out the pain-relieving properties either.
How Buprenorphine Relieves Pain
Buprenorphine is often described as a partial opioid, which might suggest it’s weaker than full opioids like morphine. For pain relief, that’s misleading. Research now widely accepts that buprenorphine acts essentially as a full pain reliever while occupying only 5 to 10 percent of opioid receptors to achieve that effect. Milligram for milligram, it is roughly 30 times more potent than oral morphine.
A meta-analysis covering 41 comparisons and over 2,500 patients found that buprenorphine actually reduced pain intensity more than full-strength opioids in acute postoperative settings. Patients receiving buprenorphine were 60 percent less likely to need additional pain medication, and the average duration of pain relief lasted about 8.5 hours. Side effects were comparable between buprenorphine and traditional opioids.
Buprenorphine also has a unique safety advantage. A study in healthy volunteers showed that doubling the dose did not increase respiratory depression, the most dangerous opioid side effect and the primary cause of overdose deaths. This “ceiling effect” on breathing exists without a corresponding ceiling on pain relief, making buprenorphine inherently safer at higher doses than drugs like oxycodone or fentanyl. It also blocks a pain-amplifying pathway that other opioids can trigger with long-term use, potentially making it more effective over time than traditional opioids that lose their effectiveness as tolerance builds.
When Providers Prescribe Suboxone for Pain
The most common scenario is a patient who has both chronic pain and opioid use disorder. In this situation, Suboxone treats the addiction while simultaneously providing pain relief, addressing both problems with a single medication. The VA system, for example, recognizes that any provider with the appropriate DEA license can prescribe buprenorphine/naloxone for pain management alongside opioid dependence.
Prescribing Suboxone purely for pain in someone without opioid use disorder is less common and more restricted. Within the VA health system, this use is limited to specially waivered providers. In general practice, some clinicians do prescribe it off-label for chronic pain when other treatments have failed, but it remains an unconventional choice. The dosing schedule often differs from addiction treatment. For pain, providers typically split the daily dose into two or three smaller doses throughout the day, since buprenorphine’s pain-relieving effects wear off faster than its ability to suppress cravings.
Side Effects Worth Knowing About
Suboxone shares common opioid side effects: constipation, nausea, headache, drowsiness, and sweating. Because buprenorphine is a partial agonist, these effects tend to be milder than with full opioids, though they don’t disappear entirely.
One lesser-known risk applies to any buprenorphine product dissolved in the mouth. In 2022, the FDA issued a warning after identifying 305 reports of serious dental problems, including tooth decay, cavities, oral infections, and tooth loss, in patients using these medications. Some cases appeared as early as two weeks after starting treatment, though the typical timeline was about two years. These problems occurred even in patients with no prior dental history. In 71 of those cases, teeth had to be extracted.
If you take Suboxone or any sublingual buprenorphine product, you can reduce this risk with a simple routine: after the film or tablet fully dissolves, take a large sip of water, gently swish it around your teeth and gums, and swallow. Wait at least an hour before brushing, since the acidic environment in your mouth right after dissolving the medication can make tooth enamel more vulnerable to abrasion.
How Suboxone Compares to Pain-Specific Formulations
If your provider is considering buprenorphine specifically for pain, there are FDA-approved options designed for that purpose. The transdermal patch delivers a low, steady dose through the skin and is changed weekly. The buccal film is placed inside the cheek and taken twice daily. Both avoid the sublingual route’s dental concerns to some degree, and both were studied in clinical trials specifically for their pain-relieving effects.
Suboxone tablets and films come in higher doses (typically 2 to 16 mg of buprenorphine) geared toward addiction treatment, while pain-specific formulations use much lower doses. The patch, for instance, delivers micrograms per hour rather than milligrams. For someone with chronic pain but no history of opioid dependence, these dedicated pain formulations are the more straightforward, on-label choice. Suboxone becomes relevant mainly when pain and opioid use disorder overlap, or when a provider determines that its specific formulation offers advantages for a particular patient’s situation.